Bolsonaro says Brazil didn’t spend cent on Bharat Bio vax deal under probe
President Jair Bolsonaro on Thursday said Brazil never paid for or received any doses of a coronavirus vaccine developed by Indian company Bharat Biotech, in response to allegations of irregularities in a deal that is under investigation.
Federal prosecutors a special Senate committee are investigating the deal for Bharat Biotech’s Covaxin shot, citing the fact that the government struck a speedy agreement when offers from Pfizer in 2020 at a lower price were ignored at the time.
“We didn’t spend one cent on Covaxin. We didn’t receive one dose of Covaxin. What sort of corruption is this?” Bolsonaro said.
The president pledged to take action if any corruption was discovered in his government. Bolsonaro said the price for the Bharat vaccines was broadly in line with other countries.
He said the government’s position has always been to only carry out purchases of vaccines after they are approved for use by federal health authority Anvisa.
Covaxin has yet to receive approval for public use, although it has received permission to conduct a phase 3 clinical trial via a Brazilian partner company.
On Wednesday, Bharat Biotech said in a statement that it had yet to provide vaccine supplies to Brazil that it has been consistent transparent in its pricing with all governments.
(Only the headline picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information commentary on developments that are of interest to you have wider political economic implications for the country the world. Your encouragement constant feedback on how to improve our offering have only made our resolve commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed updated with credible news, authoritative views incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better more relevant content. We believe in free, fair credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism subscribe to Business Standard.